Janssen

General Information

Janssen Pharmaceutica N.V., a pharmaceutical company of Johnson & Johnson, provides medicines for an array of health concerns in several therapeutic areas, including: attention deficit hyperactivity disorder (ADHD), general medicine (acid reflux disease, infectious diseases), immunology and inflammation (rheumatoid arthritis, psoriasis and inflammatory bowel diseases), mental health (bipolar I disorder, schizophrenia), neurologics (Alzheimer’s disease, epilepsy, migraine prevention and treatment), pain management, and women’s health.

Janssen R&D recognizes the important unmet medical need for new treatments for autism spectrum disorder (ASD). Collaborative opportunities in a pre-competitive represent an important methodology to create technical and scientific advances necessary for treatments of core and associated symptoms of ASD to be developed. Janssen’s participation in the prior EU-AIMS initiative, planned participation in the AIMS-2-TRIALS initiative, as well as in the NIMH Autism Biomarker Consortium –Clinical Trial initiative via the Foundation for the National Institute of Health’s Autism Biomarkers Consortium reflect the commitment of Janssen to new science in this important therapeutic area.

Role in AIMS-2-TRIALS

Janssen is actively developing a system of tools and technologies (Janssen Autism Knowledge Engine [JAKE®]) to optimize clinical trials for ASD. This includes mobile and web-based tools, as well as biosensors. Janssen’s contributions will focus on development of putative biomarkers of ASD, and the development of the European Clinical Research Network for ASD. In-kind knowledge contributions of scientific and technical expertise and advice will be provided. This advice will be supported with key learnings and data from ongoing research studies related to the system under development at Janssen, as well as expertise in clinical drug development. This includes active expert attendance and participation in consortium meetings and initiatives, document-based review and writing, and other collaborative activities.